

Meningococcal Vaccines – Provider Version



This document lays out the recommended adolescent vaccinations for Meningococcal disease in the United States. Each of these have been approved by the FDA for administration within the United States. Brand names, manufacturers, and recommendations for each vaccination is provided below.

Vaccination Name	Formula	Manufacturer	Serogroups Covered	Standing Recommendations	Age Range & Number of Doses	Vaccination Package Inserts
Routinely Recommended: Quadrivalent Meningococcal Conjugate Vaccines						
Menactra	MenACWY-D (also known as an MCV4)	Sanofi Pasteur Inc.	A,C,W,Y	<p>Recommended for ages:</p> <ul style="list-style-type: none"> • 11-12 years old, first dose (out of 2); Booster dose at 16 years old. • 13-18 years old, first dose (out of 2) if not previously vaccinated at ages 11-12; Booster dose at 16 years old. • Age 19-21; not typically recommended but may be given a catch up 	<ul style="list-style-type: none"> • Ages 2 through 55 years old as a single dose series* • Children 9 months through 23 months as a 2-dose series 3 months apart. 	http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf
Menveo	MenACWY-CRM (also known as an MCV4)	GlaxoSmithKline	A,C,W,Y	<p>Recommended for ages:</p> <ul style="list-style-type: none"> • 11-12 years old, first dose (out of 2); Booster dose before 16th birthday • 13-18 years old, first dose (out of 2) if not previously vaccinated; Booster dose before 16th birthday • Age 19-21; not typically recommended but may be given a catch up 	<ul style="list-style-type: none"> • In infants 2 months old, a 4 dose series is administered at 2, 4, 6, and 12 months of age. • In children 7 to 23 months old, a 2-dose series is administered, with the 2nd dose administered at 2 years old and at least 3 months after the first. • In children 2-10 years of age, a 2-dose series is administered with the second dose 2 months after the 1st. • Ages 11 through 55 years old as a single dose series* 	http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf

Vaccination Name	Formula	Manufacturer	Serogroups Covered	Standing Recommendations	Age Range & Number of Doses	Vaccination Package Inserts
Recommended for High Risk: Meningococcal Polysaccharide & Meningococcal Conjugate Vaccines						
Menomune	MPSV4 – polysaccharide vaccination	Sanofi Pasteur Inc.	A,C,W,Y	Only vaccine licensed and available for adults ≥56 years old.	Approved for all ages ≥2 years old as a single dose series	http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM308370.pdf
Serogroup B Meningococcal (MenB) Vaccines						
Trumenba	MenB-FHbp	Wyeth Pharmaceuticals	B	May be administered to adolescents 16-23 years old; the preferred age for MenB vaccination is 16-18 years old The second and third doses are administered at 2 and 6 months, respectively, after the first dose	Ages 10 through 25 years old as a 2 or 3-dose series	http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM421139.pdf
Bexsero	MenB-4C	GlaxoSmithKline	B	May be administered to adolescents 16-23 years old; the preferred age for MenB vaccination is 16-18 years old The second dose is administered at least 1 month after the first.	Ages 10 through 25 years old as a 2-dose series	http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM431447.pdf

*note: a booster dose may be given to individuals 15 through 55 years old who are at a continued risk

Resources

<http://www.immunize.org/cata.d/p4210.pdf> - Meningococcal Q&A
<http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM308370.pdf> - package insert for Menomune
<http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf> - package insert for Menactra
<http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf> - package insert for Menveo
<http://www.cdc.gov/mmwr/pdf/rr/rr6202.pdf> - MMWR - Meningococcal Immunization Practices (ACWY)
<http://www.cdc.gov/mmwr/volumes/65/wr/pdfs/mm6543a3.pdf> - HIV positive persons
<http://www.cdc.gov/mmwr/pdf/wk/mm6441.pdf#page=11> - Men B information/recommendations (page 11 start)
<http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM421139.pdf> - package insert for Trumenba
<http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM431447.pdf> - package insert for Bexsero